{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:09:13Z","timestamp":1778800153509,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.anai.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:11:35Z","timestamp":1770970295000},"page":"531-537.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tezepelumab\u2019s effects on patient-reported symptoms in severe asthma, overall and with history of comorbid chronic rhinosinusitis with nasal polyps (CRSwNP)"],"prefix":"10.1016","volume":"136","author":[{"given":"Njira L.","family":"Lugogo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Kay","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia F.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shradha","family":"Chandarana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-7336","authenticated-orcid":false,"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.02.002_bib0001","unstructured":"Global Initiative for Asthma. 2024 Global strategy for asthma management and prevention. Accessed April 15, 2025. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf"},{"key":"10.1016\/j.anai.2026.02.002_bib0002","unstructured":"Global Asthma Network. The global asthma report 2022. Accessed April 15, 2025. Available at: https:\/\/www.globalasthmareport.org\/resources\/Global_Asthma_Report_ 2022.pdf"},{"issue":"suppl 1","key":"10.1016\/j.anai.2026.02.002_bib0003","first-page":"22","article-title":"Severe asthma in adults","volume":"31","author":"Wenzel","year":"2005","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.anai.2026.02.002_bib0004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/PROM.S392666","article-title":"Content validation of patient-reported sleep measures and development of a conceptual model of sleep disturbance in patients with moderate-to-severe, ucontrolled asthma","volume":"14","author":"Khan","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"issue":"19","key":"10.1016\/j.anai.2026.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2026.02.002_bib0006","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.02.002_bib0007","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1038\/s41598-020-79697-x","article-title":"The prevalence of sleep disturbance among asthmatic patients in a tertiary care center","volume":"11","author":"Alanazi","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.anai.2026.02.002_bib0008","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s11325-011-0616-8","article-title":"Sleep quality and asthma control and quality of life in non-severe and severe asthma","volume":"16","author":"Luyster","year":"2012","journal-title":"Sleep Breath"},{"issue":"4","key":"10.1016\/j.anai.2026.02.002_bib0009","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/02770903.2015.1126846","article-title":"Effects of poor asthma control, insomnia, anxiety and depression on quality of life in young asthmatics","volume":"53","author":"Sundbom","year":"2016","journal-title":"J Asthma"},{"issue":"3","key":"10.1016\/j.anai.2026.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2026.02.002_bib0011","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.02.002_bib0012","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jaci.2022.12.058","article-title":"Tezepelumab efficacy by SNOT-22 score in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR","volume":"151","author":"Jacobs","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.02.002_bib0013","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention (2022 update). Accessed April 15, 2025. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2022\/07\/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf"},{"issue":"1","key":"10.1016\/j.anai.2026.02.002_bib0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.anai.2023.08.594","article-title":"Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab","volume":"132","author":"Ferri","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.02.002_bib0015","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anai.2026.02.002_bib0016","article-title":"White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA","volume":"3","author":"De Prins","year":"2022","journal-title":"Front Allergy"},{"issue":"9","key":"10.1016\/j.anai.2026.02.002_bib0017","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/biomedicines9091096","article-title":"The role of dupilumab in severe asthma","volume":"9","author":"Ricciardolo","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.anai.2026.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.02.002_bib0019","unstructured":"Food and Drug Administration (FDA). Highlights of Prescribing Information. DUPIXENT\u00ae (dupilumab). Accessed October 1, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s042lbl.pdf"},{"key":"10.1016\/j.anai.2026.02.002_bib0020","unstructured":"Food and Drug Administration (FDA). NUCALA (mepolizumab) Prescribing Information. Accessed April 29, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf"},{"key":"10.1016\/j.anai.2026.02.002_bib0021","unstructured":"Food and Drug Administration (FDA). XOLAIR\u00ae (omalizumab) Prescribing Information. Accessed April 29, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103976s5225lbl.pdf"},{"key":"10.1016\/j.anai.2026.02.002_bib0022","first-page":"S35","article-title":"Effect of dupilumab on improving physical activity in patients with severe asthma","volume":"58","author":"Sher","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2026.02.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2024.104310","article-title":"Dupilumab improves sleep quality in chronic rhinosinusitis with nasal polyps","volume":"45","author":"Riva","year":"2024","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"10.1016\/j.anai.2026.02.002_bib0024","article-title":"The effect of biologics in lung function and quality of life of patients with united airways disease: a systematic review","volume":"3","author":"Dominguez-Ortega","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"1","key":"10.1016\/j.anai.2026.02.002_bib0025","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.anai.2026.02.002_bib0026","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.anai.2026.02.002_bib0027","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.02.002_bib0028","unstructured":"Food and Drug Administration (FDA). TEZSPIRE\u00ae (tezepelumab) Prescribing Information. Accessed December 15, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761224s006lbl.pdf"},{"issue":"1","key":"10.1016\/j.anai.2026.02.002_bib0029","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12325-024-03006-5","article-title":"Effect of tezepelumab on sino-nasal outcome test (SNOT)-22 domain and symptom-specific scores in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps","volume":"42","author":"Jacobs","year":"2024","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.anai.2026.02.002_bib0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.anai.2022.12.002","article-title":"The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma","volume":"130","author":"Sher","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.02.002_bib0031","unstructured":"St George\u2019s Respiratory Questionnaire Original. English version. Accessed September 10, 2025. Available at: https:\/\/www.citystgeorges.ac.uk\/research\/support\/researcher-development\/the-st-georges-respiratory-questionnaire"},{"issue":"2","key":"10.1016\/j.anai.2026.02.002_bib0032","doi-asserted-by":"crossref","first-page":"AB100","DOI":"10.1016\/j.jaci.2023.11.329","article-title":"Efficacy of biologics in patients with moderate-to-severe, uncontrolled asthma and nasal polyps","volume":"153","author":"Peters","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.02.002_bib0033","first-page":"OA1651","article-title":"Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS\/NP) in LIBERTY ASTHMA QUEST","volume":"52","author":"Pavord","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2026.02.002_bib0034","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaip.2019.07.016","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis","volume":"8","author":"Maspero","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.02.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir Med"},{"issue":"22","key":"10.1016\/j.anai.2026.02.002_bib0036","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.02.002_bib0037","unstructured":"Global Initiative for Asthma. GINA main report: global strategy for asthma management and prevention. Accessed May 15, 2025. Available at: http:\/\/ginasthma.org\/gina-reports\/"},{"key":"10.1016\/j.anai.2026.02.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107344","article-title":"Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma","volume":"218","author":"Maspero","year":"2023","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2026.02.002_bib0039","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s41030-025-00292-4","article-title":"Physical activity in adults with severe asthma on-treatment with biological therapies: a 1-year retrospective analysis of real-world data","volume":"11","author":"Reilly","year":"2025","journal-title":"Pulm Ther"},{"issue":"11","key":"10.1016\/j.anai.2026.02.002_bib0040","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.jaip.2023.07.008","article-title":"Enabling adults with severe asthma to exercise: a qualitative examination of the challenges for patients and health care professionals","volume":"11","author":"Apps","year":"2023","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:32:11Z","timestamp":1778797931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1081120626000578"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.002","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tezepelumab\u2019s effects on patient-reported symptoms in severe asthma, overall and with history of comorbid chronic rhinosinusitis with nasal polyps (CRSwNP)","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}